Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1192

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Blood (2020) 136 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2020-143816

Published: 2020

Journal Articles

Final Analysis of the International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL in Response after R-CHOP, the Remarc Study from Lysa

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136511

Published: 2020

Journal Articles

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-135818

Published: 2020

Journal Articles

Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-137245

Published: 2020

Journal Articles

Detection of Del(17p) in Hematological Malignancies By Imaging Flow Cytometry

Wendy N. Erber, MD, Henry Hui, PhD, Jason Stanley, BSc (Hons), Thomas Mincherton, BSc, Kathryn Clarke, PhD, Bradley Augustson, MBBS FRACP FRCPA, Teng Fong Ng, BSc, MBBS, MRCP, Chan Yoon Cheah, MBBS, Andrew David McQuillan, MBBS, FRACP, FRCPA, Kathy Fuller, PhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-143323

Published: 2020

Journal Articles

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140403

Published: 2020

Journal Articles

High Dose Valaciclovir As CMV Prophylaxis in Allogeneic Hematopoietic Stem Cell Recipients at High Risk of CMV Reactivation

Genevieve Douglas, B.App.Sc MBBS FRACP FRCPA, Michelle K Yong, MBBS, FRACP, MPH, PhD, Shio Yen Tio, MBBS, FRACP, Maggie Chau, BPharm(Hons) MClinPharm MBusMgt BCOP, Joe Sasadeusz, MBBS FRACP PhD, Monica Slavin, MBBS FRACP, Mingdi Xie, BNurs GradDip, David Ritchie, MB ChB, PhD FRACP, FRCPA, Lynette C.Y. Chee, MBBS,PhDFRACP,FRCPA

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-141764

Published: 2020

Journal Articles

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139332

Published: 2020

Journal Articles

Two Rare Cases of Severe Autoimmune Dyserythropoiesis without Any Underlying Haematological Malignancy or Autoimmune Disease

James A Paterson, MD, Angela Hwang, MBBS, Stephen Wong, MBBS, FRCPA, William Sewell, MBBS, FRCPA, Joanne E. Joseph, MBBS, MD FRACP, FRCPA, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-142281

Published: 2020

Journal Articles

Recurrent and Refractory Hemophagocytic Lymphohistiocytosis in an Elderly. Role of Immune Aberration Due to Myeloid Gene Mutation

Suthanthira kannan Ramamoorthy, MDFRCPA,FRCP, Tina Noutsos, BS,MBBS,FRACP,FRCPA, David Wei, MBBS,FRCPA, Alexandra Yasmin Laidman, MBBS, Ferenc Szabo, FRACP,FRCPA

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-133776

Published: 2020

Journal Articles

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Jose Valentín García Gutiérrez, MD PhD, Jerald P. Radich, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD PhD, Tamas Masszi, MD PhD Prof., Andrzej Hellmann, MD PhD, Jesper Stentoft, MD PhD, María Teresa Gomez Casares, MD PhD, Eibhlin Conneally, MB, PhD MRCP, MRCPath, Philipp D le Coutre, MD, Norbert Gattermann, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MD FRCPI, FRCPath, Paola Aimone, MD, Sai Li, MD PhD, Ksenia Titorenko, MS, David M. Ross, MD MBBS, PhD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-137388

Published: 2020

Journal Articles

Donor-Derived T-Cells Specific for WT1 and PRAME in Combination with T-Cells Specific for Multiple Pathogens for Prevention of Relapse and Infection after Haemopoietic Stem Cell Transplant (HSCT) for Acute Myeloid Leukaemia (AML) or High-Risk Myelodysplasia (MDS) - (The INTACT Trial)

Wei Jiang, MBBS, M Clin MD FRACP, FRCPA, Emily Blyth, B. MDHons), FRACP, FRCPA, PhD, Peter J. Shaw, MA,FRACP, Leighton Edward Clancy, BSc, PhD, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, Abir Bhattacharyya, MBBS, FRACP, FRCPA, Elissa Atkins, RN, Selmir Avdic, PhD, Gaurav Sutrave, MBBS, FRACP, FRCPA, Janine Street, BSc MSc (Hons), David Gottlieb, MBBS, MD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 38.

https://doi.org/10.1182/blood-2020-143136

Published: 2020

Journal Articles

Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Luke Coyle, MBBS, FRACP, FRCPA, Nicholas J. Morley, Alessandro Rambaldi, MD, Kylie D. Mason, MBBS, MD FRACP, FRCPA, PhD, Gregor Verhoef, MD PhD, Caroline Furness, Rajendra Desai, Noemi Mergen, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-141117

Published: 2020

Journal Articles

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Peter Mollee, FRACP,MBBS,MSc,FRCPA, John Reynolds, PhD, Wojt Janowski, FRCPA,FRACP, Hang Quach, MDFRACP,FRCPA,MBBS, Philip Campbell, MBBS, Simon D. Gibbs, FRACP, FRCPA, MBBS, Sophie Lee, FRACP, FRCPA, PhD, James D'Rozario, MBBS, FRACP, FRCPA, Kerry Taylor, FRACP,FRCPA,MBBS, Tara Cochrane, MBBS,FRCPA,FRACP, Craig Thomas Wallington-Beddoe, BSc,MBBS,PhDFRACP,FRCPA, Fiona Kwok, FRACP,FRCPA,MBBS, Nicholas Weber, MBBS, Ian H. Kerridge, FRACP FRCPA MPhil BA, Helen Weston, MBBS, FRACP, FRCPA, Phoebe Joy Ho, MBBS,DPhil,FRACP,FRCPA, Noemi Horvath, MB ChB FRACP FRCPA, Flora Yuen, BBiomedSc, Andrew Spencer

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-138394

Published: 2020

Journal Articles

Implementation of Flow Cytometric Monocyte Repartition Assay for Assessment of Chronic Myelomonocytic Leukaemia (CMML) in Bone Marrow

Sharon A Allen, MBBS, B.MDci(Path), Eugene Ng, BSc, Suzanne Edwards, GDipMStat, GDipMa, BN, Uwe H Hahn, MBBS, MD FRCPA, Tatjana Banovic, MBBS, MD PhD FRCPA, David M Ross, MBBS, PhD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-140932

Published: 2020

Journal Articles

Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-134928

Published: 2020

Journal Articles

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Jan A. Burger, MD PhD, Tadeusz Robak, MDPhD, Fatih Demirkan, MD, Osnat Bairey, MD, Carol Moreno, MD PhD, David Simpson, MBChB, FRACP, FRCPA, Talha Munir, MBBS, Don A. Stevens, MD, Sandra Dai, PhD MS, Leo W. K. Cheung, PhD, Kevin Kwei, PhD, Indu Lal, MD, Emily Hsu, PhD, Thomas J. Kipps, MD PhD, Alessandra Tedeschi, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-134437

Published: 2020

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study

Meletios A Dimopoulos, Hang Quach, MDFRACP,FRCPA,MBBS, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD, David S. Siegel, MD PhD, Katja Weisel, MD, Maria Gavriatopoulou, Albert Oriol, MD, Neil K Rabin, Ajay Nooka, MDMPH, Ming Qi, MD PhD, Bifeng Ding, Anita Zahlten-Kumeli, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-137602

Published: 2020

Journal Articles

Significant EBV Reactivation Is Associated with Poorer Overall Survival Due to Increased NRM Post Myeloablative/Reduced Intensity, T-Cell Deplete Allogeneic Stem Cell Transplant for MDS or Acute Leukaemia

Ashvind Anand Prabahran, MBBS, James Anton Kuzich, MBBS, Andrew B M Lim, MBBS, FRACP, FRCPA, Eric Wong, MDPhD FRACP, FRCPA, David Ritchie, MB ChB, PhD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-142053

Published: 2020

Journal Articles

Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study

Ola Landgren, MD PhD, Katja Weisel, MD, Laura Rosinol Dachs, Philippe Moreau, MD, Mehmet Turgut, MD, Roman Hajek, MD PhD, Peter Mollee, FRACP,MBBS,MSc,FRCPA, Jin Seok Kim, MD PhD, Jianqi Zhang, Ning Go, PhD, Christopher L. Morris, PhDMD, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-141291

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Final Analysis of the International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL in Response after R-CHOP, the Remarc Study from Lysa

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

Detection of Del(17p) in Hematological Malignancies By Imaging Flow Cytometry

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

High Dose Valaciclovir As CMV Prophylaxis in Allogeneic Hematopoietic Stem Cell Recipients at High Risk of CMV Reactivation

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Two Rare Cases of Severe Autoimmune Dyserythropoiesis without Any Underlying Haematological Malignancy or Autoimmune Disease

Recurrent and Refractory Hemophagocytic Lymphohistiocytosis in an Elderly. Role of Immune Aberration Due to Myeloid Gene Mutation

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Donor-Derived T-Cells Specific for WT1 and PRAME in Combination with T-Cells Specific for Multiple Pathogens for Prevention of Relapse and Infection after Haemopoietic Stem Cell Transplant (HSCT) for Acute Myeloid Leukaemia (AML) or High-Risk Myelodysplasia (MDS) - (The INTACT Trial)

Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Implementation of Flow Cytometric Monocyte Repartition Assay for Assessment of Chronic Myelomonocytic Leukaemia (CMML) in Bone Marrow

Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study

Significant EBV Reactivation Is Associated with Poorer Overall Survival Due to Increased NRM Post Myeloablative/Reduced Intensity, T-Cell Deplete Allogeneic Stem Cell Transplant for MDS or Acute Leukaemia

Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only